NV103 Archives » ADC Review

NanoValent Receives Patent for Targeted Polymerized Nanoparticles in Cancer Treatment

NanoValent Pharmaceuticals, a development stage pharmaceutical company progressing a new class of therapeutic anti-cancer agents called targeted nanospheres (TNS), has received United States Patent...

NanoValent Pharmaceuticals and Children’s Hospital Los Angeles Sign Exclusive Global Licensing...

Sonia Portillo

Earlier today, NanoValent Pharmaceuticals, a privately-held development-stage cancer-focused pharmaceutical company advancing antibody-drug conjugate or ADC therapeutics, confirmed signing a licensing agreement with Children's Hospital...

Tag: NV103

NanoValent Receives Patent for Targeted Polymerized Nanoparticles in Cancer Treatment

NanoValent Pharmaceuticals and Children’s Hospital Los Angeles Sign Exclusive Global Licensing...

Latest

Preclinical Data Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors, Resulting in Tumor Regression...

Loncastuximab Tesirine Demonstrates an Overall High Response Rates in Pivotal Phase II Single-agent Trial

First ‘Intelligent Ligase-dependent Conjugation’ Enabling ADC Receives FDA IND Clearance

Peer Review

Addressing the Challenges of Bioconjugate Medicines

How the Next Generation Antibody Drug Conjugates Expands Beyond Cytotoxic Payloads for Cancer Therapy

Modeling and Optimization of Antibody-drug Conjugate Production Using Process Intensified Solid-phase Method